Inclusion Criteria:

- Histologically confirmed malignant advanced solid tumour, which is refractory to
standard therapies (except Group 8 patients who must not be platinum refractory) or
for which no suitable effective standard therapy exists

- Patients must have adequate organ and bone marrow function measured within 7 days
prior to administration of study treatment

- Female patients must have evidence of non-child bearing status: negative urine or
serum pregnancy test within 7 days of study treatment for women of child bearing, or
postmenopausal status

Exclusion Criteria:

- Patients receiving chemotherapy, radiotherapy (except for palliative reasons) or any
other anti-cancer therapy within 4 weeks of the last dose prior to study entry.
Patients may continue the use of biphosphonates for bone metastases and
corticosteroids

- Patients with symptomatic uncontrolled brain metastases

- Major surgery within 2 weeks of starting study and patients must have recovered from
any effects of any major surgery

- Patients who are platinum refractory (Group 8 only)

- Patients with myelodysplastic syndrome/acute myeloid leukaemia (Group 8 only).